While there is no cure for IgAN, the most prevalent form of glomerulonephritis worldwide, timely diagnosis and treatment can effectively mitigate disease progression and enhance patient outcomes. Current IgAN management encompasses lifestyle modifications and medications such as renin-angiotensin-aldosterone system (RAAS) inhibitors and immunosuppressants. However, the need for more efficacious treatments persists. This activity explores the evolving treatment landscape in IgAN, and faculty will use patient cases to address issues like expedited diagnosis, the current standard of care, mechanisms of action for emerging treatments, data from recent clinical trials, and practical strategies for optimizing individualized patient care.
Advancing IgAN Care: Expert Strategies for Transformative Patient Outcomes
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Jürgen Floege, MD
Senior Professor
RWTH Aachen University Hospital
Aachen, GermanyDr. Floege has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AstraZeneca, Boehringer, Calliditas, Chinook, Novartis, Omeros, Roche, Stadapharm, Travere
Other: Data Safety Monitoring Boards in studies of Novo Nordisk, VisterraFaculty:
Uyen Huynh-Do, MD
Associate Professor
Division of Nephrology & Hypertension
Inselspital, University Hospital Bern
Bern, SwitzerlandDr. Huynh-Do has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Alexion, AstraZeneca, Boehringer, CSL Vifor, GSK, Novartis, Otsuka
Patent Holder: HemoTherapeuticsReviewers/Content Planners/Authors:
- Ann Early has nothing to disclose.
- Cindy Davidson has nothing to disclose.
- Howard Green has nothing to disclose.
- Hany Ibrahim, MD, has nothing to disclose.
- Andrea Mathis has nothing to disclose.
- Brian McDonough, MD, FAAFP, has nothing to disclose.
- Kathleen Sheridan, PhD, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Evaluate the benefits and limitations of the current standard of care for patients with IgA nephropathy (IgAN)
- Analyze data from recent and ongoing IgAN clinical trials
- Develop individualized treatment strategies to optimize outcomes in patients with IgAN
Target Audience
This activity is designed to meet the educational needs of the practicing nephrologist as well as physicians, nurses, physician assistants, nurse practitioners, pharmacists, and all other healthcare providers involved in managing patients with immunoglobulin A nephropathy (IgAN).
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until June 26, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.25 contact hours/0.025 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-24-060-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.Commercial Support
This activity is supported by an independent educational grant from CSL Vifor.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtellignce. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Kelly Chenlei Li, MBBS, FRACP
Paul Bennett, RN, MHSM, PhD, FISN
Thilo Krüger, MD, PhD
Khalil El Karoui, MD
Federico Alberici, MD, PhD
Joel Topf, MD
James Burton, MD
- CME/CE
Incorporación de terapias dirigidas en la planificación del tratamiento de la VAA
0.25 creditsDavid Jayne, MD
Bernhard Hellmich, MD